Full-Time

Senior Scientist

Computational Biology

Korro Bio

Korro Bio

51-200 employees

RNA editing-based therapeutics discovery and development

Compensation Overview

$150k - $200k/yr

+ Equity-based compensation

Cambridge, MA, USA

Hybrid

Category
Biology & Biotech
Required Skills
Scikit-learn
Python
R
MLflow
Docker
AWS
Pandas
NumPy
Requirements
  • Ph.D. in Computational Biology, Bioinformatics, Genomics, Computational Chemistry, or a related quantitative discipline, with 3+ years of post-PhD experience in a biotech or pharmaceutical industry setting.
  • Academic-only or pure-technology industry experience will not be considered for this role.
  • Demonstrated track record of shipped, decision-impacting analyses on industry programs — e.g., target validation, biomarker discovery, oligonucleotide or small-molecule pharmacology, or preclinical-to-clinical translation.
  • Strong scientific programming in R and/or Python, with proficiency in standard biological data analysis libraries (Bioconductor, tidyverse, pandas, numpy, scikit-learn, etc.).
  • Solid experience analyzing Next-Generation Sequencing data, including RNA-seq differential expression workflows, variant calling, and quality control of sequencing experiments.
  • Familiarity with oligonucleotide or RNA-based therapeutics — including chemical modifications, delivery modalities (GalNAc, LNP), and the analytical considerations specific to antisense oligonucleotides, small interfering RNA, or related modalities.
  • Working knowledge of statistical modeling appropriate to biological data: linear and generalized linear models, mixed-effects models, multiple testing correction, and basic experimental design.
  • Comfort working with messy, real-world experimental data and collaborating directly with bench scientists to refine analytical questions.
  • Excellent written and oral communication skills, including the ability to translate technical results for non-computational stakeholders.
Responsibilities
  • Drive computational biology analyses across Korro’s research pipeline, including target validation, mechanism-of-action studies, and characterization of RNA editing activity in preclinical models.
  • Design, execute, and interpret NGS-based experiments (RNA-seq, variant calling, targeted amplicon sequencing) in support of oligonucleotide design, screening, and pharmacology workstreams.
  • Partner with platform biology, chemistry, and pharmacology teams to translate experimental questions into rigorous analytical workflows and to communicate results in a form that informs program decisions.
  • Develop and maintain reproducible analysis pipelines in R and/or Python, leveraging existing Data Science infrastructure (Posit Connect, MLflow, containerized environments, AWS).
  • Contribute analytical support to the preclinical-to-clinical translational handoff for our GalNAc-conjugated programs, including PK/PD characterization and biomarker analysis as programs mature.
  • Collaborate with cross-functional stakeholders to scope new analyses, set realistic timelines, and deliver results that are technically sound and decision-ready.
  • Mentor junior scientists and contractors on best practices in scientific computing, reproducibility, and statistical rigor.
  • Share findings through internal presentations and contribute to the scientific community through publications or presentations as appropriate.
Desired Qualifications
  • Experience analyzing clinical or translational data — Phase 1 PK/PD, biomarker time-courses, or exposure-response analyses — is a strong plus.
  • Familiarity with hepatology, metabolic disease, or other indications relevant to GalNAc-conjugated oligonucleotide therapeutics.
  • Experience with cloud-based analytical infrastructure (AWS), containerized workflows (Docker), and reproducible reporting tools (Posit Connect, Quarto, R Markdown).
  • Prior contribution to Investigational New Drug enabling packages or regulatory submissions.
  • Peer-reviewed publications in computational biology, genomics, or therapeutic pharmacology.
  • Hands-on experience using agentic coding assistants (e.g., Claude Code, Cursor, GitHub Copilot) in a production scientific computing context, with a thoughtful perspective on where these tools accelerate work and where human review remains essential.

Korro Bio develops RNA-based therapies using RNA editing to modify protein function, aiming to treat serious diseases with few or no current options. The approach targets RNA itself, enabling single base edits in transcripts to change how proteins work, which can adjust disease pathways without altering the DNA. These therapies are intended to be developed and brought to market through direct development or partnerships, with revenue coming from therapy sales, licensing, and collaborations. The company focuses on research and development to translate human genetics insights into treatments, working with healthcare providers, patients, and academic partners. Overall, Korro Bio seeks to move RNA editing toward real therapies that can help patients around the world by offering precise, targeted interventions at the RNA level.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • $85M PIPE in 2025 extends cash runway through H2 2028.
  • Novo Nordisk partnership develops cardiometabolic candidates since Sept 2024.
  • KRRO-121 advances for urea cycle disorders and hepatic encephalopathy.

What critics are saying

  • KRRO-110 trial failed functional protein levels, causing 80% stock drop.
  • Beam Therapeutics' base editing outpaces Korro in AATD liver delivery.
  • Intellia CRISPR AATD enters Phase 1 with 50% NHP protein correction.

What makes Korro Bio unique

  • OPERA platform co-opts endogenous ADAR for precise single-base RNA edits.
  • CHORD oligonucleotides enable high specificity without off-target DNA risks.
  • Targets liver diseases like AATD using precedented manufacturing and delivery.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Korro Bio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

8%

2 year growth

10%
Maeil Business Newspaper
Mar 9th, 2026
Korro Bio raises $85M PIPE to fund operations through H2 2028

Korro Bio has raised $85 million through a private investment in public equity (PIPE) round led by new investor Bainrock Healthcare Capital Partners. The company issued 4.5 million ordinary shares at $11.11 per share and 3.1 million pre-funded warrants at $11.109 per share. Combined with $85.2 million in cash and cash equivalents as of 31 December 2025, the funding extends Korro Bio's cash runway through the second half of 2028. The capital will accelerate development of its RNA editing platform OPERA, including clinical programmes KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Citigroup, Cantor, Oppenheimer and William Blair served as placement agents. Analysts forecast continued losses through 2027 despite projected revenue growth.

Investing.com
Mar 9th, 2026
Korro Bio raises $85 million in private equity financing By Investing.com

Korro Bio raises $85 million in private equity financing

Stock Titan
Jan 7th, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Investing.com
Oct 16th, 2024
KRRO stock soars to 52-week high, touches $98 amid robust gains

In other recent news, Korro Bio has announced a strategic partnership with Novo Nordisk (NYSE:NVO), a global healthcare company, to develop genetic medicines for cardiometabolic diseases.

BioSpace
Sep 16th, 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Bio announces collaboration with Novo Nordisk to develop two therapeutic candidates.